Inivata Launches Clinical Trial Using InVisionFirst(R) Lung

In conjunction with the Lyon, France-based Centre Leon Berard, Inivata has announced a phase III clinical trial focused on diagnosing patients suspected of having metastatic lung cancer. The study will be the first to use Inivata’s InVisionFirst(R) Lung ctDNA liquid lung biopsy test.

The study will focus on people suspected of having metastatic non-small cell lung cancer. The study, which seeks to determine whether the InVisionFirst test can provide accurate results while reducing the time it takes to develop an appropriate treatment. The test results can then be compared with those from standard diagnostic measures.

Recruitment of participants expected to last 18 months and will enroll 286 people across 17 clinical sites in France. Testing will be randomized at a 1:1 ratio, between those using the InVisionFirst testing procedure and those receiving standard diagnostic measures.

Since 2018, Stacy Chick has served as the Chief Commercial Officer of Inivata, a Cambridge UK and Morrisville, North Carolina-based cancer genomics company, transitioning the company from a research-based to a thriving commercial organization while transforming the lives of cancer patients and their families through the power of liquid biopsy.